What is the recommended dose of clindamycin (antibiotic) for a 14-year-old patient weighing 78kg with a Staphylococcus (staph) infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clindamycin Dosing for Staphylococcus Infections in a 14-year-old Weighing 78kg

For a 14-year-old patient weighing 78kg with a Staphylococcus aureus infection, the recommended clindamycin dosage is 30-40 mg/kg/day divided into 3-4 equal doses for oral therapy, or 40 mg/kg/day divided into 3-4 doses for parenteral therapy. 1, 2

Specific Dosing Recommendations

Oral Clindamycin

  • For this 78kg patient:
    • Total daily dose: 2,340-3,120 mg/day (30-40 mg/kg/day)
    • Divided into 3-4 equal doses:
      • If 3 doses: 780-1,040 mg every 8 hours
      • If 4 doses: 585-780 mg every 6 hours

Parenteral (IV) Clindamycin

  • For this 78kg patient:
    • Total daily dose: 3,120 mg/day (40 mg/kg/day)
    • Divided into 3-4 equal doses:
      • If 3 doses: 1,040 mg every 8 hours
      • If 4 doses: 780 mg every 6 hours

Dosing Based on Type of Staph Infection

Methicillin-Susceptible S. aureus (MSSA)

  • Parenteral therapy: Clindamycin 40 mg/kg/day divided every 6-8 hours (alternative to first-line agents) 1
  • Oral therapy: Clindamycin 30-40 mg/kg/day divided into 3-4 doses (alternative to first-line oral cephalexin) 1

Methicillin-Resistant S. aureus (MRSA), Clindamycin-Susceptible

  • Parenteral therapy: Clindamycin 40 mg/kg/day divided every 6-8 hours (preferred option along with vancomycin) 1
  • Oral therapy: Clindamycin 30-40 mg/kg/day divided into 3-4 doses (preferred oral option) 1

Treatment Duration Considerations

  • For uncomplicated skin/soft tissue infections: 5-10 days 3
  • For moderate infections: 10-14 days 3
  • For β-hemolytic streptococcal infections: at least 10 days 2
  • For severe infections or deeper tissue involvement: 2-4 weeks 3

Important Clinical Considerations

Susceptibility Testing

  • Always confirm susceptibility of the isolate to clindamycin before committing to therapy, especially for MRSA 3
  • Be aware of inducible clindamycin resistance (D-test should be performed) 3

Monitoring

  • Monitor for gastrointestinal side effects, particularly diarrhea 2
  • If significant diarrhea occurs, discontinue therapy due to risk of C. difficile infection 2, 4

Limitations and Cautions

  • Clindamycin is not considered a first-line drug for single S. aureus infections except in cases of penicillin allergy 4
  • For severe infections, consider combination therapy or alternative agents 3
  • Development of resistance during therapy has been reported, particularly in endocarditis 5
  • For osteomyelitis, longer treatment duration (4 weeks or more) may be required for effective treatment 6

Administration

  • Oral clindamycin should be taken with a full glass of water to avoid esophageal irritation 2
  • For this adolescent patient who can swallow capsules, standard capsule formulations are appropriate 2

Practical Application

For this 14-year-old patient weighing 78kg, the most appropriate dosing would depend on the severity of infection and whether oral or parenteral therapy is indicated. Given the patient's age and weight, adult dosing ranges may be appropriate, but should not exceed the calculated pediatric mg/kg dosing.

For oral therapy, a practical regimen would be 300-450 mg every 6 hours or 450-600 mg every 8 hours, staying within the 30-40 mg/kg/day recommendation while using available capsule strengths.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Staphylococcus aureus Infections in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Clindamycin as an anti-staphylococcal agent--indications and limitations.

Scandinavian journal of infectious diseases. Supplementum, 1984

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.